Literature DB >> 19417649

Endothelial progenitor cell: ongoing controversy for defining these cells and their role in neoangiogenesis in the murine system.

Mervin C Yoder1, David A Ingram.   

Abstract

PURPOSE OF REVIEW: We highlight some recent high-profile articles in which the study results and interpretations, upon comparison, convey the controversy and disparate views prevalent in the field when defining the role of murine bone marrow-derived endothelial progenitor cells in the process of tumor neoangiogenesis. RECENT
FINDINGS: Highlighted articles identify a critical role for these cells in promoting the angiogenic switch for growth of metastatic tumors or find no role at all for these circulating cells as engrafting cells in vascular endothelium or as promoters of tumor growth. We suggest potential strategies to further document cell identities as a guide for future studies and provide some alternative interpretations of the published studies highlighted in this review that, if considered, may diminish the current polar views.
SUMMARY: To fully appreciate the orchestrated cellular events participating in new vessel formation in the tumor microenvironment, better methods of cell identification and functional validation will be necessary to specify which cells in which tumors are facilitating and forming new vessels in which tissues at which stage of the disease.

Entities:  

Mesh:

Year:  2009        PMID: 19417649     DOI: 10.1097/MOH.0b013e32832bbcab

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  36 in total

1.  Bone marrow is a reservoir for proangiogenic myelomonocytic cells but not endothelial cells in spontaneous tumors.

Authors:  Andrew C Dudley; Taturo Udagawa; Juan M Melero-Martin; Shou-Ching Shih; Adam Curatolo; Marsha A Moses; Michael Klagsbrun
Journal:  Blood       Date:  2010-05-07       Impact factor: 22.113

Review 2.  The evolution of endothelial regulatory paradigms in cancer biology and vascular repair.

Authors:  Joseph W Franses; Elazer R Edelman
Journal:  Cancer Res       Date:  2011-12-05       Impact factor: 12.701

Review 3.  Stem cells, cell therapies, and bioengineering in lung biology and diseases. Comprehensive review of the recent literature 2010-2012.

Authors:  Daniel J Weiss
Journal:  Ann Am Thorac Soc       Date:  2013-10

4.  Discovery and Characterization of a Potent and Specific Peptide Ligand Targeting Endothelial Progenitor Cells and Endothelial Cells for Tissue Regeneration.

Authors:  Dake Hao; Wenwu Xiao; Ruiwu Liu; Priyadarsini Kumar; Yuanpei Li; Ping Zhou; Fuzheng Guo; Diana L Farmer; Kit S Lam; Fengshan Wang; Aijun Wang
Journal:  ACS Chem Biol       Date:  2017-03-02       Impact factor: 5.100

5.  Stem cells and cell therapies in lung biology and lung diseases.

Authors:  Daniel J Weiss; Ivan Bertoncello; Zea Borok; Carla Kim; Angela Panoskaltsis-Mortari; Susan Reynolds; Mauricio Rojas; Barry Stripp; David Warburton; Darwin J Prockop
Journal:  Proc Am Thorac Soc       Date:  2011-06

Review 6.  Endothelial progenitor cells: quo vadis?

Authors:  Matthew R Richardson; Mervin C Yoder
Journal:  J Mol Cell Cardiol       Date:  2010-07-29       Impact factor: 5.000

7.  PTK7+ Mononuclear Cells Express VEGFR2 and Contribute to Vascular Stabilization by Upregulating Angiopoietin-1.

Authors:  Sunil K Chauhan; Hyung Keun Lee; Hyun Soo Lee; Eun Young Park; Eunae Jeong; Reza Dana
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-05-21       Impact factor: 8.311

Review 8.  Regenerative pulmonary medicine: potential and promise, pitfalls and challenges.

Authors:  Piero Anversa; Mark A Perrella; Stella Kourembanas; Augustine M K Choi; Joseph Loscalzo
Journal:  Eur J Clin Invest       Date:  2012-03-21       Impact factor: 4.686

9.  Isolation and characterization of circulating lymphatic endothelial colony forming cells.

Authors:  Terri A DiMaio; Breanna L Wentz; Michael Lagunoff
Journal:  Exp Cell Res       Date:  2015-11-17       Impact factor: 3.905

10.  CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.

Authors:  L Vroling; J S W Lind; R R de Haas; H M W Verheul; V W M van Hinsbergh; H J Broxterman; E F Smit
Journal:  Br J Cancer       Date:  2009-12-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.